Skip to content

MassBio

Massachusetts Biotechnology Council

Open search form
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
  • Resources
    • 2023 Diversity, Equity, & Inclusion Report
    • 2023 Industry Snapshot
    • 2022 Massachusetts Biopharma Funding Report
    • 2022 MA Life Sciences Workforce Analysis Report
    • Economic Development
    • Biopharma Startup Toolkit
    • Career Center
    • MassBioEd
  • Events
    • Events Calendar
    • Overview of Events
    • Get Involved
  • Membership
    • Member Directory
    • Benefits of Membership
    • Savings and Rewards
    • Member News
    • Become a Member
    • Member Rates
    • Pay Company Dues
  • Savings & Rewards
    • MassBioEdge
  • Conference Center
    • MassBioHub
  • Programs
    • Bioversity at Southline Boston
    • State of Possible 2025 Report
    • Diversity, Equity, and Inclusion
    • Policy & Advocacy
    • Partnering Opportunities
    • MassBioDrive
    • Digital Health
    • BioReady Communities
  • About Us
    • About Us
    • News & Thought Leadership
    • Sponsorship Opportunities
    • Staff
    • Board of Directors
    • FAQs
    • Contact Us
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
Open search form

Member Directory

Click to Open Main Menu

FERRER INTERNACIONAL

Life Sciences | Drug Development
Barcelona, Spain +34 93 600 3700 Website

Overview

FERRER’S PUBLIC BENEFIT PHILOSOPHY

At Ferrer we want to promote a new way of doing business and a responsible way of being in the world. We want to make a positive impact in society while running a successful pharmaceutical enterprise. Our business is not an end in itself, but a means to generate positive global impact. Our conviction is such that the company’s strategic plan consists of three pillars that define what we want to achieve: great people, a livable planet, and social justice. In its mission, Ferrer has exceeded global B Corp standards in terms of social and environment performance, transparency, and corporate responsibility – and in all the territories for which it has a direct presence (https://ferrer.com/en/Ferrer-becomes-a-bcorp). Over the last four years, the company has placed increasing focus on achieving transformation as a positive global and social impact organization. Our purpose, our strategy and our achievements are present in our corporate identity and slogan: “Ferrer for good”.

FERRER’S GROWTH AREAS:  RARE PULMONARY AND NEUROLOGY DISORDERS

Ferrer is a privately owned, multinational pharma company with a growing presence in rare diseases. Ferrer has built a franchise in pulmonary hypertension in Europe and has initiated another business initiative in amyotrophic lateral sclerosis, beginning with a partnership focused on clinical development of an oral therapy in Europe. Our partnering activities are centered on in-licensing of clinical stage programs in rare neurology and pulmonary disorders, and out-licensing of non-core programs. As an integrated company, Ferrer maintains streamlined, end-to-end operating capabilities. Its gendered-balanced executive team is currently leading Ferrer’s transformation journey as it aims to research, develop, and commercialize transformative solutions that make a positive impact in society.

Company News

Training

Register & explore a multi-stakeholder approach for rare disease R&D in Europe, June 4, 2023

May 05, 2023

Posted by FERRER INTERNACIONAL

News

Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor from Asceneuron, exclusively to treat Progressive Supranuclear Palsy (PSP)

Feb 22, 2023

Posted by FERRER INTERNACIONAL

See all Members

Massachusetts Biotechnology Council

700 Technology Square, 5th Floor
Cambridge, MA 02139
617.674.5100

  • Contact
  • Privacy Policy
  • Fulfillment Policy
  • © 2024 All Rights Reserved